Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018. doi:10.3322/caac.21492
   Web of Science ®Google Scholar
• Orangio GR. The economics of colon cancer. Surg Oncol Clin N Am. 2018;27:327–347. doi:10.1016/j.soc.2017.11.00729496093
   PubMed Web of Science ®Google Scholar
• Baskar R, Yap SP, Chua KL, Itahana K. The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance. Am J Cancer Res. 2012;2:372–382.22860229
   PubMed Web of Science ®Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–627. doi:10.1146/annurev.med.53.082901.10392911818492
   PubMed Web of Science ®Google Scholar
• Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–1137. doi:10.1002/(ISSN)1097-014216080176
   PubMed Web of Science ®Google Scholar
• Brockman RW. Mechanisms of resistance to anticancer agents. Adv Cancer Res. 1963;7:129–234.14153765
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci. 2007;28:326–333. doi:10.1016/j.tips.2007.05.00517573126
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–670. doi:10.1038/nbt.228722781695
   PubMed Web of Science ®Google Scholar
• Roberts MS, Groene WS, Lorence RM, Bamat MK. Naturally occurring viruses for the treatment of cancer. Discov Med. 2006;6:217–222.17250786
   PubMedGoogle Scholar
• Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett. 2007;254:178–216. doi:10.1016/j.canlet.2007.02.00217383089
   PubMed Web of Science ®Google Scholar
• Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5:e1115641. doi:10.1080/2162402X.2015.111564126942095
   PubMed Web of Science ®Google Scholar
• Fountzilas C, Patel S, Mahalingam D. Review: oncolytic virotherapy, updates and future directions. Oncotarget. 2017;8:102617–102639. doi:10.18632/oncotarget.v8i6029254276
   PubMedGoogle Scholar
• Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther. 2008;10:32–37.18228179
   PubMed Web of Science ®Google Scholar
• Freeman SM, Abboud CN, Whartenby KA, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274–5283.8221662
   PubMed Web of Science ®Google Scholar
• Loya SM, Zhang X. Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator. Gene Ther. 2015;22:237–246. doi:10.1038/gt.2014.11325567538
   PubMed Web of Science ®Google Scholar
• Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, Norris JS. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 2003;10:330–339. doi:10.1038/sj.cgt.770057612679806
   PubMed Web of Science ®Google Scholar
• Bateman A, Bullough F, Murphy S, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 2000;60:1492–1497.10749110
   PubMed Web of Science ®Google Scholar
• Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Exp Ther. 2000;60:6396–6402.
   Google Scholar
• Krabbe T, Altomonte J. Fusogenic viruses in oncolytic immunotherapy. Cancers (Basel). 2018;10.
   Web of Science ®Google Scholar
• Stanford MM, Shaban M, Barrett JW, et al. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther. 2008;16:52–59. doi:10.1038/sj.mt.630034817998900
   PubMed Web of Science ®Google Scholar
• Bartee MY, Dunlap KM, Bartee E. Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res. 2017;77:2952–2963. doi:10.1158/0008-5472.CAN-16-163828314785
   PubMed Web of Science ®Google Scholar
• Burton C, Das A, McDonald D, et al. Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme. Oncolytic Virother. 2018;7:107–116. doi:10.2147/OV.S17933530538967
   PubMed Web of Science ®Google Scholar
• Johnston JB, Barrett JW, Chang W, et al. Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol. 2003;77:5877–5888. doi:10.1128/JVI.77.10.5877-5888.200312719581
   PubMed Web of Science ®Google Scholar
• Smallwood SE, Rahman MM, Smith DW, McFadden G. Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol. 2010;Chapter 14:Unit 14A 11. doi:10.1002/9780471729259.mc14a01s17
   Google Scholar
• Wolfe AM, Dunlap KM, Smith AC, Bartee MY, Bartee E. Myxoma virus M083 is a virulence factor which mediates systemic dissemination. J Virol. 2018;92. doi:10.1128/JVI.02186-17
   Web of Science ®Google Scholar
• Chan WM, Bartee EC, Moreb JS, Dower K, Connor JH, McFadden G. Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol. 2013;87:4445–4460. doi:10.1128/JVI.03488-1223388707
   PubMed Web of Science ®Google Scholar
• Bartee E, Chan WM, Moreb JS, Cogle CR, McFadden G. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012;18:1540–1551. doi:10.1016/j.bbmt.2012.04.00422516053
   PubMed Web of Science ®Google Scholar
• Orabi A, Hussein A, Saleh AA, El-Magd MA, Munir M. Evolutionary insights into the fusion protein of Newcastle disease virus isolated from vaccinated chickens in 2016 in Egypt. Arch Virol 2017;162(10):3069–3079. doi:10.1007/s00705-017-3483-1. Epub 2017 Jul 8
   Google Scholar
• Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T. Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. J Virol 2015:30;90(6):3065–3073.
   Google Scholar
• Chua KB, Koh CL, Hooi PS, et al Isolation of Nipah virus from Malaysian Island flying-foxes. Microbes Infect. 2002;4:145–151.11880045
   PubMed Web of Science ®Google Scholar
• Neill JD, Ridpath JF, Valayudhan BT. Identification and genome characterization of genotype B and genotype C bovine parainfluenza type 3 viruses isolated in the United States. BMC Vet Res. 2015;11:112.25976921
   PubMed Web of Science ®Google Scholar
• Wang F, Ma Y, Barrett JW, et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol. 2004;5:1266–1274. doi:10.1038/ni113215502830
   PubMed Web of Science ®Google Scholar
• Bartee E, Bartee MY, Bogen B, Yu XZ. Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics. 2016;3:16032. doi:10.1038/mto.2016.3227933316
   PubMed Web of Science ®Google Scholar